Abstract: Certain piperazinyl- and piperidinyl-substituted cyclohexanes have anti-ischemic properties.

Abstract: A series of novel indol-3-ylalkyl derivatives of alkoxypyrimidinylpiperazines are disclosed as Formula I. ##STR1## These compounds are intended to be useful agents for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.

Abstract: A series of pyprimidinyl compounds of formulae I, II and III; ##STR1## wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and hydroxy;R.sup.3 is selected from hydrogen, hydroxy, or oxo, with the proviso that R.sup.3 can only be oxo when R.sup.1 and R.sup.2 are hydrogen, and further that R.sup.1, R.sup.2, and R.sup.3 cannot all be hydrogen or hydroxy at the same time; andthe solid and dotted lines refer to either a double covalent bond or a single covalent bond with another hydrogen atom covalently bonded to the carbon terminus end.The compounds of this invention possess cognition and memory enhancing activity.

Abstract: Certain 1-indolylalkyl-4-(alkoxypyrimidinyl)piperazines of Formula I are useful antidepressant agents. The ##STR1## substituents R.sup.1, R.sup.2 and R.sup.5 are hydrogen or lower alkyl; R.sup.3 and R.sup.4 are hydrogen, alkyl, alkoxy, alkythio, carboxamido, halo, or trifluoromethyl; R.sup.6 is alkoxy; and n is the integer 2 or 3.

Abstract: An improved process, suitable for adaption to large-scale manufacture for synthesis of the cerebral function enhancing agent BMY 21502.

Abstract: A series of 1,4-disubstituted piperazine derivatives comprised of indol-3-ylalkyl and substituted pyridin-2-yl substituent groups. These compounds are useful as antidepressant agents.

Abstract: A series of diazinylpiperidine compounds of Formula I ##STR1## wherein X is an ethylene chain or a 1,2-benzo ring; Y is carbonyl or methylene; R.sup.1 is hydrogen or lower alkyl; and Z is an R.sup.2, R.sup.3 -disubstituted diazinyl ring selected from pyridazine, pyrimidine, and pyrazine ring systems. Pharmacologic and neuroanatomical testing demonstrates that compounds of the series act to enhance cerebral function in mammals, particularly when there is a deficit in normal cerebral functioning. Specific pharmacologic test results indicate that compounds of Formula I possess cognition and memory enhancing activity.

Abstract: A series of nootropic compounds of the following formula: ##STR1## and its pharmaceutically acceptable acid addition salts, wherein: R.sup.2 is hydrogen, lower alkyl, aryl which is optimally substituted, or hetaryl;R.sup.7 is hydrogen or is combined with R.sup.9 as a fused benzo-ring;R.sup.8 is hydrogen or lower alkyl; andR.sup.9 is lower alkyl, or R.sup.9 can be combined with R.sup.8 to give a 2-pyrrolidinone, a phthalimide, or isoindolone ring system.Pharmacological testing demonstrates that the series possesses cognition and memory enhancing actions and/or mild CNS simulation.